The Epidemiology of Tuberculosis
Scott Lindquist MD MPH
Washington State Communicable Disease Epidemiologist
Reported TB Cases
United States, 1982–2013*

TB Morbidity
United States, 2008–2013

TB Case Rates,* United States, 2013

*Updated as of June 11, 2014.
Map of U.S.-Affiliated Pacific Islands by TB Case Rates, 2013

TB Case Rates, U.S.-Affiliated Pacific Islands, 2013

United States overall: 3.0
Hawaii: 8.2
American Samoa: 3.7
Palau: 28.4
Guam: 29.9
Northern Mariana Islands: 31.3
Federated States of Micronesia: 121.5
Marshall Islands: 219.4

Comparative Incidence – U.S. and WA
**TB Case Rates** by Age Group
United States, 1993–2013

Cases per 100,000

*Updated as of June 11, 2014.

**Crude Incidence by Select Age Groups – WA**

Cases per 1000 population

*Updated as of June 11, 2014.

**Trends in TB Cases in Foreign-born Persons, United States, 1993 – 2013**

No. of Cases

*Updated as of June 11, 2014.
TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993 – 2013

Proportional Disease Burden by Origin – WA

TB Case Rates by Age Group and Race/Ethnicity, United States, 2013

*All races are non-Hispanic. Persons reporting two or more races accounted for less than 1% of all cases.
Proportional Disease Burden by Race/Ethnicity – WA¹

Crude Incidence by Race/Ethnicity – WA²

Years from Arrival to TB Diagnosis – WA Cases with Origins Outside U.S. Proper, 2009-2014¹,²

¹ AIAN: American Indian or Alaskan Native.
² NHOPI: Native Hawaiian or Other Pacific Islander.
Select Medical Risk Factors – WA Cases, 2009-2014.¹,²

¹ Medical risks recorded at diagnosis, as documented or reported by provider.
² Immunosuppressing conditions include: TNF alpha-antagonist therapy, post-organ transplantation, and other immunosuppression.

Number of MDR-TB Cases estimated among notified pulmonary TB cases 2013

MDR-TB Treatment Outcomes, 2007-11
Primary Anti-TB Drug Resistance, United States, 1993 – 2013

Note: Based on initial isolates from persons with no prior history of TB. MDR-TB defined on initial DST.

Primary MDR TB, United States, 1993 – 2013

Note: Based on initial isolates from persons with no prior history of TB. MDR-TB defined on initial DST.

XDR TB Case Count Defined on Initial DST by Year, 1993 – 2013

Note: Extensively drug-resistant TB (XDR-TB) is defined as resistance to isoniazid and rifampin, plus resistance to any fluoroquinolone and at least one of three injectable second-line anti-TB drugs.
Select Classes of Drug-resistance – Annual Case Counts and Period Totals – WA

1st-line poly-resistant: Isolate resistance to two or more 1st-line drugs (not MDR).
MDR: Isolate resistance to Isoniazid and Rifampin.
Pre-XDR: Isolate resistance to Isoniazid, Rifampin, and 2nd-line injectable agent OR fluoroquinolone.

Treatment Start Within 7 Days of Sputum Smear (+) Specimen Collection

NTIP: National TB Indicators Project.
Specimen Collection: AFB smear (+) on sputum.
Data: Treatment start = 14 days prior to specimen collection date.
Collection date = 7 days from date of data analyses.

Sputum Culture Conversion within 60 Days of Treatment Start

Eligible cases: Patients alive at diagnosis, with (+) initial sputum culture; initiating treatment with ≥1 TB drug.
Excluding: Patients dying or moving out of U.S. within 60 days of treatment start; Tx start > 120 days prior to date of data export for analyses with conversion disposition pending; Converted specimen collection date precedes Tx start date.
Eligible cases: Patients alive at diagnosis initiating treatment with >=1 TB drug.
Excludes: Rifampin resistance; Meningeal site; <=14 y.o. with disseminated disease; Death or move out of U.S. within 12 mos. of treatment start; Tx start > 365 days prior to date of data export for analysis with disposition pending; Tx stop date prior to Tx start date; "Not TB."

How Do We Compare?

How Do We Compare?
How Do We Compare?

Immigrant and Refugee Follow-up – Process Outcomes by Year of Arrival

*Records evaluated include all persons entering the U.S. under an immigrant, refugee, or asylee visa, assigned to the classification of B1 or B2, as per 1991 or 2007 Technical Instructions.